New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial

Table 2 Change of hepatic fat content from baseline after 12 wk of treatment

Treatment group	Full analysis set				Per protocol set
	n	Baseline	12 wk	P value	n	Baseline	12 wk	P value
Placebo, %	23	11.96 ± 7.46	12.57 ± 8.34		20	12.59 ± 7.70	13.59 ± 8.47
Low dose, %	23	13.33 ± 7.11	12.12 ± 6.33	0.3861	20	12.99 ± 6.86	11.37 ± 6.02	0.1641
High dose, %	22	16.05 ± 7.05	14.34 ± 7.19	0.0332	20	16.12 ± 7.19	14.77 ± 7.15	0.0392

¹Two sample t-test;

²Wilcoxon’s rank sum test. Continuous data are expressed as mean ± SD.